





# ACTMED study

#### Page 1

# ActMed Study: Access to medicines during the last year of life

We would like to seek your views on providing patients and carers with access to medicines during the last year of life, and on what facilitates and prevents good practice. Your experience will contribute to a comprehensive overview of practice which will help shape national policy.

What do we mean when we refer to medicines access?

- Medicines Regular and as necessary medicines, administered via all routes used for symptom management during the last year of life (excluding 'just-in-case' boxes).
- Access prescribing, dispensing, supply and associated information-giving about medicines and information about access to medicines

The questionnaire will take approximately 10-15 minutes to complete. It is designed for all healthcare professionals, with supplementary questions for non-medical prescribers and community pharmacists.

If you have any queries about the research please contact Dr Natasha Campling, ActMed Senior Research Fellow, via email at actmed@soton.ac.uk

Thank you in advance for your help with this important study

Professor Sue Latter Chief Investigator

This study has been funded by the NIHR Health Services and Delivery Research programme (HS&DR 16/52/23) and this survey is approved by the HRA (IRAS number 231837)

Please tick the box to consent to take part in this survey

Lagree to take part

#### **SECTION A: YOUR ROLE**

A1 How would you describe your role?	<b>A1</b>	How	would	you	describe	your	role?
--------------------------------------	-----------	-----	-------	-----	----------	------	-------

- © General practitioner (please go to Question A2)
- Clinical nurse specialist working from a hospice (please go to Question A2)
- Clinical nurse specialist employed by a Community Trust (please go to Question A2)
- © Community nurse (RN) (please go to Question A2)
- Pharmacist
- Other role (please go to Question A2)

If other role, please describe		

If you are a primary care pharmacist employed by GP practice(s), does this role include:

	Yes	No
Advising patients/carers about palliative care medicines		Г
Medicines optimisation reviews for palliative care patients		

If you are a community pharmacist in a community pharmacy, do you provide as
enhanced service for palliative care (e.g. on-demand availability of specialist drugs)?

© Yes	○ No				
If yes, does this service cover:					
		Yes	No		
Stocking a locally agreed lis medicines	t of core palliative care	Г	Г		
Out-of-hours availability of p pharmacy	alliative care medicines from you	ır	Г		
Out-of-hours availability of pother linked pharmacies in y		Г			
Provision of information on to contractors and health care can signpost patients to the		Г			
Provision of information on t directly	he service to patients and carers		Г		
Is your pharmacy independent or part of a chain?					
○ Independent ○ Small multiple ○ Large multiple					
A2. Do you work out-of-hours?					
□ No	☐ Between 6.30pm - ☐ 8am weekdays	Weekends/ba	nk		

# SECTION B. ACCESS TO PALLIATIVE CARE MEDICINES PRESCRIPTIONS DURING WORKING HOURS

# B1. Which of the following are you able to provide for patients to obtain *new* prescriptions during working hours? Please select all options you use:

	Yes	No	Not applicable
Personal home visits	Г	Г	Г
Telephone consultations	Г	Г	Г
E-mail consultations	Г	Г	Г
GP practice appointments	Г	Г	Г
Community pharmacy-based appointments		Г	
Referral to a nurse prescriber		Г	
Referral to a pharmacist prescriber			Г
Referral to a GP		Г	

Other, please describe:		

new prescriptions for palliative care medicines?					
<ul><li>Not at all</li><li>Very</li></ul>	<ul><li>Slightly</li><li>Extremely</li></ul>	○ Somewhat			
B3. Are you aware of commarea that provide an enhan availability of specialist dru	ced service for palliative	ative care pharmacies') in your care (e.g. on-demand			
<ul><li>Yes</li><li>None providing services</li><li>Not aware (please go to</li></ul>					
B4. In your opinion, does a availability of specialist dru access to medicines for pa	ıgs) via community phar	<del>-</del>			
○ Yes	○ No				
Please give reasons for your response:					

B2. Overall, how satisfied are you with your ability to support patients in obtaining

(e.g. on-demand availability of specialist drugs) to patients and carers?						
C Always C Rarely	<ul><li>Often</li><li>Never</li></ul>	Sometimes				
If you do not "always" provide information on enhanced services for palliative care to patients and carers, please give reasons for your response:						

B5. How often do you provide information on enhanced services for palliative care

# SECTION C. ACCESS TO PALLIATIVE CARE MEDICINES OUT-OF-HOURS

C1. In your area, do palliative care clinical nurse specialists (CNSs) provide a 7 days a week community service between 9am - 5pm?					
○ Yes	○ No	○ Don't know			
If yes, how effective is it at fac	ilitating out-of-hours medicine	es access?			
<ul><li>○ Not at all</li><li>○ Very</li></ul>	<ul><li>Slightly</li><li>Extremely</li></ul>	○ Somewhat			
Please give reasons for your response					

C2. When a patient requires are they usually: (please se practice)		an out-of-hours consultation accurately reflects usual
	by the healthcare professional for the PR	al during the consultation ESCRIPTION of the medicine
If you selected Other, please s	pecify:	
C3. This question is about y of the services. Overall, how patients/carers how best to	v confident are you in your	-
<ul><li>○ Not at all</li><li>○ Very</li></ul>	<ul><li>Slightly</li><li>Extremely</li></ul>	○ Somewhat

# SECTION D. INFORMATION PROVISION ABOUT MEDICINES AT THE POINT OF ACCESS

# D1. When a patient/carer is in need of a prescription, dispensing and/or supply of a palliative care medicine, how often do you give the following information?

	Always	Often	Sometimes	Rarely	Never
Possible side- effects of the medicine(s)	Г	Г	Г	Г	
How to manage possible side-effects of the medicine(s)	Г	Г	Г	Г	Г
How to tell if the medicine is working	Г	Г	Г	Г	
How to tell if the medicine is not working	Г	Г	Г	Г	Г
What to do if the medicine is not working	Г	Г	Г	Г	Г
Who to contact if changes to the medicines or new medicines are required	Г	Г	Г	Γ	

# SECTION E. INTER-PROFESSIONAL COMMUNICATION ABOUT MEDICINES

# E1. Do you have access to shared patient records for communication about medicines access between health professionals? Tick all that you are able to access:

	Yes - Paper	Yes - Electronic	No
GP records		Г	Г
GP out of hours records		Г	Г
Community nurse records		Г	Г
Hospice/palliative care specialist records		Г	Г
Community pharmacy records		Г	Г
Summary Care Record		Г	

E2. In your service, is there a 'main' prescriber, who usually carries out the initial patient assessment, when a patient starts on a palliative care pathway?

© Yes		
If yes, what is their role?		
<ul><li>General practitioner</li><li>Other</li></ul>	<ul><li>Palliative care consultant</li></ul>	© Palliative care clinical nurse specialist
If you selected Other, please s	pecify:	
Is it communicated so that other	er professionals are clear wh	o the main prescriber is?
C Yes		
E3. Overall, how satisfied ar patient/carer access to med	_	ed records to facilitate
○ Not at all	<ul><li>Slightly</li><li>Extremely</li></ul>	○ Somewhat
© Very	© Extremely	
Please give reasons for your r	esponse	

#### **SECTION F. NON-MEDICAL PRESCRIBING**

# F1. Are You a Non-Medical Independent Prescriber (nurse or pharmacist prescriber) (V300 qualification)?

<ul> <li>Yes, actively prescribing as a non-medical prescriber</li> <li>Yes, but not actively prescribing</li> <li>Not a prescriber</li> <li>Not a nurse or a pharmacist (e.g. general practitioner) -please go to question F6</li> </ul>
If you are not actively prescribing please state the reasons for this:
If you are not a non-medical prescriber please state the reasons for this: ( <i>Tick all that</i>
apply)
☐ Cost of training
☐ Lack of employer/colleague support
□ No backfill available
□ No designated trainer
□ Other
If you selected Other, please specify:

If you are not a non-medical prescriber, please go to question F6

F2.	Does your	prescribing	include	controlle	d drugs	?
-----	-----------	-------------	---------	-----------	---------	---

○ Yes ○ No

#### F3. Are you able to prescribe via an electronic system?

- © Yes, the system enables transfer of the prescription to the pharmacy
- C Yes, but the system does not enable transfer of the prescription to the pharmacy
- No, prescribing pad only

#### F4. On average, how often do you prescribe palliative care medicines?

- Once a day or more 2-3 times a week
- Once a week or less

Once a month or less

#### F5. Which palliative care medicine classes do you most frequently prescribe?

	Often	Sometimes	Rarely	Never
Analgesics				
Anti-emetics	Г	Г		
Laxatives		Г		
Antifungals		Г		
Corticosteroids		Г		
Hypnotics and muscle relaxants		Г	Г	
Anti-muscarinics	Г	Г	Г	Г
Sedatives		Г		
"Specials" – unlicensed medicinal products	Г	Г	Г	Г

# F6. Overall, how frequently does non-medical prescribing (prescribing by a nurse or pharmacist) have a beneficial impact on palliative care medicines access?

<ul><li>Always</li><li>Rarely</li></ul>	○ Often ○ Never	<ul><li>Sometimes</li><li>Don't know</li></ul>	
Please give reasons	for your response		

#### SECTION G. QUESTIONS FOR COMMUNITY PHARMACISTS

If you are not a community pharmacist please go to Section H

**G1.** Palliative care medicines access issues

#### How frequently do you:

	Always	Often	Sometimes	Rarely	Never
Undertake medicines optimisation reviews for palliative care patients?	Г	Г	Г	Г	Γ
Feel that lack of awareness of patients' palliative status influences your ability to help patients access medicines	Г	Г	Г	Г	Γ
Encounter a discrepancy between palliative care medicines prescribed and the stock you hold	Г	Г	Г	Г	Г

### How frequently do you:

	Always	Often	Sometimes	Rarely	Never
Limit your stock of palliative care medicines because 'use by' dates are likely to expire	Г	Г		Γ	Γ
Limit your stock of palliative care medicines because of lack of storage space	Г	Г		Г	Г
Experience problems receiving prescriptions electronically from patients' GP practices	Г	Г		Г	Г
Encounter carers not having satisfactory identification, seeking to collect controlled drug prescriptions for patients	Г	Г		Г	Γ

#### SECTION H. OVERALL SERVICE PROVISION

H1. If you are a prescriber, medicines?	how competent do you fee	l in prescribing palliative care
<ul><li>○ Not at all</li><li>○ Very</li></ul>	<ul><li>Slightly</li><li>Extremely</li></ul>	<ul><li>Somewhat</li><li>Not applicable</li></ul>
H2. Are there possible solu	tions to any gaps or proble	ems with service delivery?
C Yes	○ No	
If yes, please describe		

We want to try and understand how effective you think the service you currently offer is. We are going to do this by asking you to think about pain management in particular.

H3. Out of a typical 100 palliative care patients during the last year of life who use your service, estimate the proportion with no pain, mild pain, moderate pain or severe pain at any one point in time.

Enter your estimates below and ensure the answers sum to 100:

No Pain
Mild Pain
Moderate Pain
Severe Pain

H4. Imagine there were no barriers to medicines access in your service and all patients could receive the medicines they need quickly. What proportions of pain severity would there be with ideal medicines access?

Enter your estimates below and ensure the answers sum to 100:

No Pain
Mild Pain
Moderate Pain
Severe Pain

#### **SECTION I. And FINALLY**

I1. If you have any other comments to make about access to medicines at end-of-life please use this space:
I2. Please tell us the first part of your work postcode, so we can map the geographical spread of responses. This will be removed from the questionnaire so your data remain anonymous.
I3. If you work in a GP practice or community pharmacy please provide your organisation ODS code (sometimes known as a J code). This will be used to map your participation with your Clinical Research Network (CRN), and removed from the questionnaire so your data remain anonymous.
○ Not applicable ○ Don't know
ODS (or J) code:

I4. In the next stage of the study we will be conducting case studies of medicines access experiences with patients, carers and healthcare professionals. Would you be willing to be contacted by the research team to discuss taking part in the next phase of our study?

	○ No
I5. If yes, please give your name and email address. These will be removed from the questionnaire so your data remains anonymous.	
Name:	
Email address:	

# Thank you for taking the time to complete this survey

ActMed Study Questionnaire Version 1 (20.07.2018)

Please return your completed survey to:

#### FREE POST RTXY-ZBLS-GJXL

Jakki Birtwistle, Research Fellow, Leeds Institute of Health Sciences,

Room 10.39, Level 10,

The Worsley Medical and Dental Building,

Clarendon Way, LEEDS LS2 9NL